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Scale-up of ART in Malawi has reduced case notification rates 
in HIV-positive and HIV-negative tuberculosis
H. Kanyerere,1 B. Girma,1,2 J. Mpunga,1 K. Tayler-Smith,3 A. D. Harries,4,5 A. Jahn,2,6  
F. M. Chimbwandira6
Human immunodeficiency virus (HIV) infection is the most important risk factor for the develop-
ment of tuberculosis (TB) in persons infected with My-
cobacterium tuberculosis, and has been responsible for 
the huge upsurge in TB cases in affected southern Afri-
can countries over the last 25 years. Antiretroviral 
therapy (ART) reverses the immune dysfunction asso-
ciated with HIV, and with initiation of treatment there 
is rapid functional recovery of mycobacteria-specific 
immune responses, which results in enhanced capac-
ity to restrict mycobacterial growth.1,2 As a result, ART 
has a potent TB preventive effect.
A systematic review and meta-analysis of 11 studies 
from 2002 to 2011 showed that ART was associated 
with a 65% reduction in TB incidence across all base-
line CD4 counts in people living with HIV (PLHIV).3 
More recent studies have confirmed these findings 
and have also highlighted the TB preventive benefits 
of early initiation of ART.4–7
At the programme level, although PLHIV are often 
initiated late on ART and with low CD4 counts, stud-
ies from Malawi and Swaziland have shown that when 
high ART coverage rates are reached among HIV-in-
fected populations, the TB case notification rate (CNR) 
decreases.8–12 In a study from Malawi reporting data 
up to 2012, there was some preliminary evidence to 
suggest that while the declines in TB were most appar-
ent in those with HIV infection, there might also be a 
decline in patients who were HIV-negative.10 This led 
to suggestions that the overall decrease in HIV-associ-
ated TB in the community might have led to reduced 
community transmission of M. tuberculosis and thus 
fewer cases of TB in the non-HIV-infected population.
We have now collected national aggregate data on 
the number of PLHIV and the number of ART and TB 
case notifications stratified by HIV status up to 2015, 
and we use these data to report on the correlation be-
tween ART scale-up and annual national TB case noti-
fications in Malawi from 2005 to 2015, with particular 
interest in whether there have been changes in 
HIV-positive as well as HIV-negative TB.
METHODS
Study design
This was a retrospective descriptive ecological study 
using aggregate data from national reports.
Setting
Malawi is one of the poorest countries in the world, 
with a rapidly growing population currently estimated 
at 17 million and a gross national income per capita 
of US$730.13 National scale-up of ART commenced in 
2004, with the number of patients alive and retained 
on treatment reported quarterly by the HIV Depart-
ment of the Ministry of Health (Lilongwe). In line 
with national and international guidelines,14,15 PLHIV 
are currently eligible for ART if they are pregnant or 
breast feeding, have World Health Organization 
(WHO) clinical Stage 3 or 4 disease, or have a CD4 cell 
count below the nationally agreed threshold (250 
cells/µl before 2010, 350 cells/µl between 2010 and 
2014 and 500 cells/µl thereafter). At the start of na-
tional scale-up, first-line treatment mainly consisted 
of a fixed-dose combination of stavudine-lamivu-
dine-nevirapine; from 2011 there was a gradual coun-
trywide change to tenofovir-lamivudine-efavirenz.
Malawi has had an established national TB control 
programme (NTP) since 1985, with case finding, diag-
nosis, registration, treatment and treatment outcomes 
consistently following agreed international guide-
lines.16 Following published operational research 
showing the benefit of HIV testing and cotrimoxazole 
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Setting: For 30 years, Malawi has experienced a dual ep-
idemic of human immunodeficiency virus (HIV) infection 
and tuberculosis (TB) that has recently begun to be at-
tenuated by the scale-up of antiretroviral therapy (ART).
Objective: To report on the correlation between ART 
scale-up and annual national TB case notification rates 
(CNR) in Malawi, stratified by HIV-positive and HIV-nega-
tive status, from 2005 to 2015.
Design: A retrospective descriptive ecological study us-
ing aggregate data from national reports.
Results: From 2005 to 2015, ART was scaled up in Ma-
lawi from 28 470 to 618 488 total patients, with popula-
tion coverage increasing from 2.4% to 52.2%. During this 
time, annual TB notifications declined by 35%, from 
26 344 to 17 104, and the TB CNR per 100 000 popula-
tion declined by 49%, from 206 to 105. HIV testing up-
take increased from 51% to 92%. In known HIV-positive 
TB patients, the CNR decreased from a high of 
1247/100 000 to 710/100 000, a 43% decrease. In known 
HIV-negative TB patients, the CNR also decreased, from a 
high of 66/100 000 to 49/100 000, a 26% decrease.
Conclusion: TB case notifications have continued to de-
cline in association with ART scale-up, with the decline 
seen more in HIV-positive than HIV-negative TB. These 
findings have programmatic implications for national TB 
control efforts.
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preventive therapy for patients found to be HIV-positive,17,18 HIV 
testing of TB patients was routinely scaled up, with uptake and 
results of testing formally and routinely captured at the national 
level from 2005 onwards.
Study population
The study population included the estimated annual number of 
PLHIV in Malawi, the number (adults and children) recorded 
alive and retained on ART at the end of each year, and all adults 
and children registered nationally each year with TB, stratified by 
HIV status, from 2005 to 2015.
Sources of data, variables and analysis
Sources of aggregate data were the national annual reports from the 
NTP and the HIV Department, Ministry of Health, Malawi. With 
the changes in ART eligibility criteria during the study period, ART 
coverage was calculated using the total HIV-infected population as 
the denominator. This was derived from national epidemiological 
projections using the Estimation and Projection package and Spec-
trum software from the Joint United Nations Programme on AIDS 
(UNAIDS, Geneva, Switzerland)19 and based on national popula-
tion estimates obtained from the Malawi National Statistics Office 
(http://www.nsomalawi.mw/publications.html). Annual TB case 
notifications were documented and TB case rates per 100 000 popu-
lation were derived from national population estimates. TB patients 
included registered cases stratified by HIV status: known HIV-posi-
tive, known HIV-negative and unknown HIV status. The numbers 
of patients with known HIV-positive TB and with known HIV-nega-
tive TB/100 000 HIV-positive and HIV-negative Malawi popula-
tions, respectively, were calculated based on the annual data from 
the UNAIDS Spectrum software and the Malawi National Statistics 
Office, as described above.19 Data were analysed descriptively.
Ethics approval
Ethics approval for the study was obtained from the Malawi Na-
tional Health Science Research Committee (Lilongwe). The Ethics 
Advisory Group of the International Union Against Tuberculosis 
and Lung Disease (Paris, France) waived the need for further inter-
national ethics approval. As records and reports of aggregate data 
were used, informed patient consent was not necessary.
RESULTS
The number of people alive and receiving ART from 2005 to 2015 
increased progressively from 28 470 to 618 488, with ART cover-
age among PLHIV rising from 2.4% to 52.2% (Figure 1).
The trends in TB case notifications and TB CNR (/100 000) are 
shown in Figure 2. Absolute numbers of TB cases peaked in 2006 
FIGURE 1 Numbers and coverage of PLHIV receiving ART, Malawi, 2005–2015. 
PLHIV = people living with the human immunodeficiency virus; ART = antiretroviral 
treatment.
FIGURE 2 Numbers of registered TB cases and CNRs, Malawi, 2005–2015. TB = 
tuberculosis; CNR = case notification rate.
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at 26 344 and had declined progressively to 17 104 by 2015, a 
35% decrease. This trend was mirrored by a decline in the TB 
CNR, from a high of 206/100 000 in 2006 to 105/100 000 in 2015, 
a 49% decrease.
Trends in absolute numbers of notified TB patients who were 
HIV-tested, along with HIV status and, for those known to be 
HIV-positive, the uptake of ART, are shown in Figure 3. The pro-
portion of TB patients who were HIV-tested in the country in-
creased from 51% in 2005 to 92% in 2015, and was stable be-
tween 2012 and 2015 (92–93%). The proportion of TB patients 
with positive HIV status declined from 69% in 2005 to 53% in 
2015, with the period 2010–2015 seeing a continual year-on-year 
decline from 64% to 53%. The proportion of HIV-positive TB pa-
tients started on ART remained at 50% between 2005 and 2009, 
but increased progressively from 2010 onwards, from 54% to 94% 
in 2015. For the 7 years when HIV testing rates were 85% 
(2009–2015), the absolute number of HIV-positive TB patients de-
creased from 13 558 to 8408 (a 38% decrease), while the overall 
change in absolute numbers of HIV-negative TB patients was 
small, decreasing from 7483 to 7420 (a 0.7% decrease).
Trends in HIV-positive TB cases /100 000 PLHIV and HIV-nega-
tive TB cases /100 000 people not infected with HIV are shown in 
Figure 4A and B. The initial increase in CNR/100 000 in the first 3 
years reflects the progressive increase in TB patients being HIV 
tested, from 51% to 65% to 83%. Thereafter, HIV testing rates 
were always 83%. In known HIV-positive TB patients, there was 
a progressive decrease in the CNR, from a high of 1247/100 000 in 
2007 to 710/100 000 in 2015, a 43% decrease. In known HIV-neg-
ative TB patients, there was also a decrease in the CNR from a 
high of 66/100 000 in 2008 to 49/100 000 in 2015, a 26% 
decrease.
DISCUSSION
This study has a number of interesting findings. First, our initial 
reports from Malawi on the pronounced inverse correlation be-
tween the national scale-up of ART and national TB case notifica-
tions are confirmed.10,12 As ART coverage increases, the absolute 
FIGURE 3 Trends in HIV testing, HIV status and ART uptake among registered TB pa-
tients, Malawi, 2005–2015. TB = tuberculosis; HIV = human immunodeficiency virus; 
ART = antiretroviral treatment.
FIGURE 4 CNRs for HIV-positive and HIV-negative TB, Malawi, 
2005–2015. A) For HIV-positive TB: case rates are known HIV-positive 
TB cases/100 000 PLHIV in Malawi. B) For HIV-negative TB: case rates 
are known HIV-negative TB cases/100 000 people not infected with 
HIV in Malawi. CNR = case notification rate; HIV = human immuno-
deficiency virus; TB = tuberculosis; PLHIV = people living with HIV.
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numbers of TB cases and the TB CNR/100 000 have continued to 
decline. This is in line with other reports and publications from 
southern Africa.11
Second, the proportion of TB patients being tested for HIV is 
now consistently greater than 90%, and in the last 2 years over 
90% of patients with HIV-associated TB have been initiated on 
ART. We have no information from this aggregate data set about 
the time of starting ART, or indeed whether ART was already be-
ing taken at the time TB was diagnosed. Nevertheless, having 
PLHIV on ART during anti-tuberculosis treatment should improve 
TB treatment outcomes—provided there is no resistance to the 
antiretroviral drugs—and should also help to prevent recurrent 
TB developing after successful completion of anti-tuberculosis 
treatment.8,20
Third, while there has been a large decrease in the absolute 
number and proportion of HIV-infected TB patients in the last 7 
years, the decrease in absolute numbers of TB patients without 
HIV infection was marginal. However, when TB-HIV status was 
assessed in relation to the CNR/100 000, there were large de-
creases both in HIV-positive TB cases/100 000 PLHIV and in the 
CNR in HIV-negative TB cases/100 000 people without HIV, al-
though these decreases were less marked compared with HIV-pos-
itive cases. These results confirm our first and preliminary find-
ings in Malawi for 2012,10 and suggest that a reduction in 
HIV-positive TB cases has a beneficial effect on transmission of M. 
tuberculosis in the community and thus fewer cases of TB in the 
non-HIV-infected population. Similar findings have recently been 
reported from a 15-year observational study in Kenya, where 
there was a 28–44% decrease in HIV-positive TB and an 11–26% 
decrease in HIV-negative TB.21
The strengths of this study are the comprehensive national re-
ports, which for TB have integrated HIV parameters since 2005, 
and the recognised quality of Malawi’s ART data.22 The limita-
tions relate mainly to the aggregate nature of the data, which rely 
on accurate TB case notifications from Malawi’s many TB registra-
tion centres, and which prevent detailed examination and expla-
nation of some of the observations, such as time of ART initiation 
in HIV-infected TB patients. We also cannot exclude the possibil-
ity that the decrease in TB notifications might have occurred as a 
result of other changes in the last 12 years, such as improved so-
cio-economic status, better coverage or quality of TB diagnosis, or 
implementation of isoniazid preventive therapy (IPT). However, 
we have no evidence of any marked improvement in socio-eco-
nomic conditions of the rural population. Changes in coverage or 
quality of TB diagnosis, such as the introduction of Xpert® MTB/
RIF (Cepheid, Sunnyvale, CA, USA), might have been expected to 
increase rather than reduce TB case notifications, and to date 
there has been no significant scale-up of IPT.
There are some important implications for moving forward. 
First, in line with the WHO’s rapid advice in 2015 and recently 
released 2016 guidelines to start all PLHIV on ART regardless of 
clinical stage or CD4 cell count,23,24 Malawi has made a strategic 
decision to start what is called ‘HIV test and treat’. Early start of 
ART has been shown to further reduce the risk of TB in PLHIV,4–7 
and this should enhance the gains already made in the past sev-
eral years. TB is also a major cause of hospitalisation and in-hospi-
tal mortality in adults and children globally, and early ART is 
likely to substantially reduce this burden.25
Second, there are plans to scale up IPT in a phased manner 
around the country. Two randomised controlled studies in Ivory 
Coast and South Africa have demonstrated that adding IPT to 
ART in PLHIV can lead to an additional reduction in TB cases of 
30% or higher,7,26 and this intervention may add to the TB pre-
ventive effect of ART. This is important because despite the effec-
tive intervention of ART, TB CNRs in PLHIV are still much higher 
than in the non-HIV-infected population.
Third, with HIV-negative TB cases decreasing, but at a rela-
tively slow rate, it is important that the Malawi NTP attend to the 
basics of TB control, including good infection control, measures 
to minimise the risk of multidrug-resistant TB and the provision 
of regular structured supportive supervision for all the registration 
units in the country.27
Fourth, Malawi needs to start recognising and addressing other 
factors that increase the risk of TB, such as undernutrition, smok-
ing, alcohol and diabetes mellitus.28 Rapid uncontrolled urbanisa-
tion together with major lifestyle changes among populations in 
sub-Saharan Africa are driving a rapidly increasing epidemic of di-
abetes mellitus,29 and there is increasing evidence to show that 
this poses a risk for TB control in terms of rising case numbers 
and worse treatment outcomes for people undergoing anti-tuber-
culosis treatment.30
In conclusion, this study provides further evidence of the con-
tinuing decline in TB notifications in association with the scale-up 
of ART in Malawi. There is a large decline in CNRs in HIV-positive 
TB, although rates are still high compared with the HIV-negative 
population. CNRs are declining in HIV-negative TB, albeit slowly. 
While efforts towards scaling up ART must continue to ensure the 
wide coverage and early start of treatment for PLHIV, Malawi must 
ensure that it provides high quality core services for TB, and it 
should also begin to address other determinants of the disease.
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Contexte  :  Pendant 30 ans, le Malawi a connu une double épidémie 
du virus de l’immunodéficience humaine (VIH) et de la tuberculose 
(TB) qui s’est atténuée récemment avec l’expansion du traitement 
antirétroviral (TAR).
Objectif  :  Etablir la corrélation entre l’expansion du TAR et les 
notifications annuelles de cas de TB, stratifiés en fonction de leur 
statut VIH positif ou négatif, au Malawi, de 2005 à 2015.
Schéma  :  Une étude rétrospective descriptive écologique reposant 
sur les données agrégées des rapports nationaux.
Résultats  :  De 2005 à 2015, le Malawi a étendu le TAR de 28 470 à 
618 488 patients, avec une couverture de la population passant de 
2,4% à 52,2%. Pendant ce temps, les notifications annuelles de TB 
ont décliné de 35%, de 26 344 à 17 104, et le taux de notification des 
cas de TB par 100 000 population a décliné de 49%, de 206 à 105. 
L’utilisation du test VIH a augmenté de 51% à 92%. Chez les patients 
TB-VIH positifs, les taux de notification des cas ont diminué d’un 
niveau élevé de 1247/100 000 à 710/100 000 (diminution de 43%). 
Chez les patients TB-VIH négatifs connus, les taux de notification des 
cas ont également décru d’un taux élevé de 66/100 000 à 49/100 000 
(diminution de 26%).
Conclusion  :  Les notifications de cas de TB ont continué à décliner en 
association avec l’expansion du TAR, avec un déclin davantage 
constaté chez les patients TB-VIH positifs que chez les patients TB-VIH 
négatifs. Ces constatations ont des implications pour les programmes 
nationaux de lutte contre la TB.  
Marco de referencia: Durante 30 años se ha presentado en Malawi 
una epidemia doble de infección por el virus de la inmunodeficiencia 
humana (VIH) y tuberculosis (TB), que se ha moderado en tiempos 
recientes gracias a la ampliación de escala de administración del 
tratamiento antirretrovírico (TAR).
Objetivo: Evaluar la relación entre la ampliación de escala del TAR y 
la tasa anual nacional de notificación de casos de TB, estratificada por 
la situación frente al VIH, en Malawi del 2005 al 2015.
Método: Fue este un estudio retrospectivo descriptivo ecológico a 
partir de los datos agregados de notificación a escala nacional.
Resultados: Del 2005 al 2015 se amplió la escala de administración 
del TAR en Malawi de 28 470 a 618 488 casos, con un aumento de la 
cobertura del 2,4% al 52,2% de la población. Durante este período 
disminuyó un 35% la notificación anual de TB, de 26 344 a 17 104 
casos, y un 49% la tasa de notificación, que pasó de 206 por 100 000 
habitantes a 105/100 000. La aceptación de la prueba diagnóstica del 
VIH aumentó del 51% al 92%. En los pacientes positivos frente al 
VIH, la tasa de notificación de TB disminuyó de 1 247/100 000 a 
710/100 000 (disminución del 43%). En los pacientes negativos 
frente al VIH, las tasas de notificación de TB también disminuyeron de 
66/100 000 a 49/100 000 (disminución del 26%).
Conclusión: La notificación de casos de TB ha continuado su 
disminución en paralelo con la ampliación de escala de 
administración del TAR; la disminución es mayor en los pacientes 
positivos frente al VIH que en los pacientes negativos. Estos resultados 
tienen consecuencias programáticas sobre las iniciativas nacionales 
de control de la TB.  
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